Navigation Links
Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
Date:9/19/2007

any's net loss per share for the three months ended June 30, 2007 will increase from $(0.21) to $(0.30) and the Company's net loss per share for the nine months ended June 30, 2007 will increase from $(1.31) to $(1.43). This amendment will have no effect on the Company's cash balances or other capital resources.

The Company expects to file an amended Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007 as promptly as practicable.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical Company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements cont
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Amendment on cloning ban rejected; vote on bill set for Wednesday
2. New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes
3. Multichannel Pipetting: How to Choose the Correct Pipettor
4. Mental research at UW-Madison could correct disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... patient visit in its Phase 2 FDG-PET clinical trial ... patients and was carried out at five sites in ...
(Date:12/3/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... of fiscal year 2010 on December 10, 2009 at 7:00 ... to discuss the results at 11:30 a.m. EST on the ... for the second quarter ended October 31, 2009 and will ...
(Date:12/3/2009)... Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: ... services for drug discovery and life sciences research, today ... imaging systems. Living Image software drives the more than ... Living Image 4.0 features advanced spectral unmixing tools to ...
(Date:12/2/2009)... Corporation (Nasdaq: MATK ) announced today that it intends ... year 2009 on December 16, 2009, at approximately 4:00 p.m. ... ET Martek will conduct a conference call to discuss these ... the call live via webcast by visiting Martek,s web site ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
... the Space Shuttle Discovery launched into space real-time health information ... using GE Healthcare's advanced heart monitoring and digital ... monitor and track the health of the astronauts during space ... experts located outside NASA's mission control center in Houston. , ...
... a provider of managed network security services, said it ... of Mycom's mailMAX Managed Services Division and ... Inc. , ,SecurePipe is a provider of managed network ... care and financial institutions. Headquarted in Illinois, about 75 ...
... R&D Magazine has selected Bruker AXS Inc.'s ... which recognizes the most technologically significant products introduced into ... system is an advanced X-ray diffraction system, a technology ... research fields. It enables users to determine small molecule ...
Other Biology Technology:
(Date:12/4/2009)... to an analysis of statewide data taken from 1998-2001, ... year were more than three times likely to report ... their insurance status during pregnancy and delivery. , ... times more likely among mothers with Medicaid coverage, and ...
(Date:12/4/2009)... heart cells, University of Iowa investigators have shown how ... kinase), disrupts the electrical activity of heart cells. ... was published online Dec. 3 in the journal ... developed great interest in calmodulin kinase II as a ...
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2U-Iowa study helps advance heart-related research 2Species down, disease up 2Species down, disease up 3Species down, disease up 4UT multimedia program increases middle school interest in science 9105 1UT multimedia program increases middle school interest in science 9105 2Brain malformations significantly associated with preterm birth Wake Forest research shows 9102 1Brain malformations significantly associated with preterm birth Wake Forest research shows 9102 2Brain malformations significantly associated with preterm birth Wake Forest research shows 9102 3Visit to the doctor 3A The supply of additional private services is increasing 50656 1Visit to the doctor 3A The supply of additional private services is increasing 50656 2
... from UC San Diego are collaborating with scientists ... to map patterns of biodiversity and land use ... combined with climate models, will project how climate ... policy for setting aside conservation easements. , Wildlife, ...
... fly alone when migrating at night. Some birds, at least, ... when they are 200 meters or more apart. , The ... Illinois Natural History Survey, appears this month in Integrative ... with statistical data what many ornithologists and observers had long ...
... This release is available in Spanish . , ... on the Earth and in the concentration of CO 2 ... positive effects on the physiology of barley plants and increases its ... of Ms Usue Prez-Lpez, defended at the University of the Basque ...
Other Biology News:Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3Birds migrate together at night in dispersed flocks, new study indicates 2Birds migrate together at night in dispersed flocks, new study indicates 3CO2 increase in the atmosphere augments tolerance of barley to salinity 2CO2 increase in the atmosphere augments tolerance of barley to salinity 3CO2 increase in the atmosphere augments tolerance of barley to salinity 4
... of your microarray data using Asuragens bioinformatics ... from consultation to extensive data analysis using ... our expertise in combination with the Gene ... microarray experiments., ,Normalization and basic statistical analysis ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... M (OSM) is a pleiotropic cytokine produced ... sarcoma cells. OSM inhibits the growth of ... fibroblast, smooth muscle and Kaposis sarcoma cell ... low density lipoprotein receptor expression on hepatoma ...
... pump series combines Harvard Apparatuss best pump mechanism, ... wide range of configuration options. A lookup table ... syringes from all the major manufacturers. A bright, ... pertinent information from across the lab. All models ...
Biology Products: